These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34017637)

  • 1. More Unnecessary Imaginary Worlds - Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Unnecessary Imaginary Worlds - Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review's Draft Evidence Report.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy.
    Langley PC
    Innov Pharm; 2019; 10(3):. PubMed ID: 34007562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
    Langley PC
    Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
    Feng Z; Tong WK; Zhang X; Tang Z
    Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
    Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
    Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies.
    Langley PC
    Innov Pharm; 2019; 10(3):. PubMed ID: 34007563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.
    Kim N; Wang J; Burudpakdee C; Song Y; Ramasamy A; Xie Y; Sun R; Kumar N; Wu EQ; Sullivan SD
    J Manag Care Spec Pharm; 2022 Jul; 28(7):740-752. PubMed ID: 35737858
    [No Abstract]   [Full Text] [Related]  

  • 17. Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom.
    Sandhu H; Xu W; Olivieri AV; Lübker C; Smith I; Antavalis V
    Adv Ther; 2023 Mar; 40(3):1282-1291. PubMed ID: 36630047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2018; 9(4):. PubMed ID: 34007726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.